What are you thoughts on navigating a new indication such as FTO, if a license is reached for cardioprotection in the US.
or, other, do you think it’s possible to sell bisantrene for cardio protection and still retain bis for FTO in the future or is it an all or nothing deal?
How would pricing work if that was the case - can we have 2 different prices for the same molecule in 2 different indications or is will the price for cardioprotection set the limit for others.
I know hypotheticals but appreciate thoughts. My holding in Neuren has sparked these questions….
I think it’s complicated…
RAC Price at posting:
$1.44 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)